These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28828990)

  • 1. Update on COX-2 Selective Inhibitors: Chemical Classification, Side Effects and their Use in Cancers and Neuronal Diseases.
    Rayar AM; Lagarde N; Ferroud C; Zagury JF; Montes M; Sylla-Iyarreta Veitia M
    Curr Top Med Chem; 2017; 17(26):2935-2956. PubMed ID: 28828990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond.
    Coruzzi G; Venturi N; Spaggiari S
    Acta Biomed; 2007 Aug; 78(2):96-110. PubMed ID: 17933277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors on experimental colitis.
    Paiotti AP; Marchi P; Miszputen SJ; Oshima CT; Franco M; Ribeiro DA
    In Vivo; 2012; 26(3):381-93. PubMed ID: 22523290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coumarins scaffolds as COX inhibitors.
    Revankar HM; Bukhari SN; Kumar GB; Qin HL
    Bioorg Chem; 2017 Apr; 71():146-159. PubMed ID: 28222891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influencing COX-2 Activity by COX Related Pathways in Inflammation and Cancer.
    Yu T; Lao X; Zheng H
    Mini Rev Med Chem; 2016; 16(15):1230-1243. PubMed ID: 27145850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?
    Hersh EV; Lally ET; Moore PA
    Curr Med Res Opin; 2005 Aug; 21(8):1217-26. PubMed ID: 16083531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scientific rationale for specific inhibition of COX-2.
    Bolten WW
    J Rheumatol Suppl; 1998 May; 51():2-7. PubMed ID: 9596548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors: indications and complications.
    Pascucci RA
    J Am Osteopath Assoc; 2002 Sep; 102(9):487-9. PubMed ID: 12361181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a potent cyclooxygenase-2 inhibitor, S4, through docking-based pharmacophore screening, in vivo and in vitro estimations.
    Tseng TS; Chuang SM; Hsiao NW; Chen YW; Lee YC; Lin CC; Huang C; Tsai KC
    Mol Biosyst; 2016 Jul; 12(8):2541-51. PubMed ID: 27265567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual acting anti-inflammatory drugs: a reappraisal.
    Bertolini A; Ottani A; Sandrini M
    Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The COXIB experience: a look in the rearview mirror.
    Marnett LJ
    Annu Rev Pharmacol Toxicol; 2009; 49():265-90. PubMed ID: 18851701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a novel COX-2 inhibitor as an orally potent anti-pyretic and anti-inflammatory drug: design, synthesis, and structure-activity relationship.
    Hayashi S; Sumi Y; Ueno N; Murase A; Takada J
    Biochem Pharmacol; 2011 Oct; 82(7):755-68. PubMed ID: 21741371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cyclooxygenase-2 inhibitors: safety and effectiveness.
    Kaplan-Machlis B; Klostermeyer BS
    Ann Pharmacother; 1999 Sep; 33(9):979-88. PubMed ID: 10492503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COX-2 inhibitors: pharmacological data and adverse effects.
    Mattia C; Coluzzi F
    Minerva Anestesiol; 2005; 71(7-8):461-70. PubMed ID: 16012420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surface plasmon resonance studies and biochemical evaluation of a potent peptide inhibitor against cyclooxygenase-2 as an anti-inflammatory agent.
    Somvanshi RK; Kumar A; Kant S; Gupta D; Singh SB; Das U; Srinivasan A; Singh TP; Dey S
    Biochem Biophys Res Commun; 2007 Sep; 361(1):37-42. PubMed ID: 17640617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Athletes, NSAID, coxibs, and the gastrointestinal tract.
    Lilly KF
    Curr Sports Med Rep; 2010; 9(2):103-5. PubMed ID: 20220352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective COX-2 inhibitors as anticancer agents: a patent review (2014-2018).
    Mahboubi Rabbani SMI; Zarghi A
    Expert Opin Ther Pat; 2019 Jun; 29(6):407-427. PubMed ID: 31132889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacology of selective COX-2 inhibitors.
    Capone ML; Tacconelli S; Sciulli MG; Patrignani P
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):49-58. PubMed ID: 14552704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonsteroidal antiinflammatory drugs: past, present and future.
    Patrono C; Rocca B
    Pharmacol Res; 2009 May; 59(5):285-9. PubMed ID: 19416627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs: gastrointestinal-sparing potential drugs.
    Singh R; Kumar R; Singh DP
    J Med Food; 2009 Feb; 12(1):208-18. PubMed ID: 19298218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.